Ocular Therapeutix Share Price (NASDAQ: OCUL)

$12.37

▲

-0.25

(-1.98%)

Live

Last updated on August 18, 2025 at 11:48 PM IST

$₹

Check the interactive Ocular Therapeutix Stock chart to analyse performance

Ocular Therapeutix stock performance

as on August 18, 2025 at 11:48 PM IST

Today's Low:$12.22
Today's High:$12.65
$12.37
1.21%
Downside
Day's Volatility :3.4%
Upside
2.21%
52 Weeks Low:$5.79
52 Weeks High:$12.91
$12.37
53.23%
Downside
52 Weeks Volatility :55.19%
Upside
4.18%

Ocular Therapeutix Stock Returns

Period	Ocular Therapeutix Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	68.04%	2.3%	0.0%
6 Months	75.28%	-5.8%	0.0%
1 Year	44.56%	-10.9%	0.0%
3 Years	141.3%	2.8%	-11.6%

Ocular Therapeutix Inc Key Stats

Check Ocular Therapeutix key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$12.62
Open	$12.59
Today's High	$12.65
Today's Low	$12.22
Market Capitalization	$2.2B
Today's Volume	$1.7M
52 Week High	$12.91
52 Week Low	$5.785
Revenue TTM	$56.7M
EBITDA	$-237.3M
Earnings Per Share (EPS)	$-1.26
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-63.41%

Stock Returns calculator for Ocular Therapeutix Stock including INR - Dollar returns

The Ocular Therapeutix stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Ocular Therapeutix investment value today

Current value as on today

₹1,45,769

Returns

₹45,769

(+45.77%)

Returns from Ocular Therapeutix Stock

₹41,695 (+41.7%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Ocular Therapeutix Stock

-33%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Ocular Therapeutix Stock from India on INDmoney has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Ocular Therapeutix Inc

Name
Holdings %
Name
Holdings %
Deep Track Capital, LP
8.27%
SUMMER ROAD LLC
8.03%
VR Adviser, LLC
7.38%
BlackRock Inc
6.95%
Vanguard Group Inc
4.85%
venBio Select Advisor LLC
4.28%

Analyst Recommendation on Ocular Therapeutix Stock

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Ocular Therapeutix(by analysts ranked 0 to 5 stars)

Ocular Therapeutix Share Price Target

What analysts predicted

Upside of 41.1%

Target:

$17.45

Current:

$12.37

Ocular Therapeutix share price target is $17.45, a slight Upside of 41.1% compared to current price of $12.37 as per analysts' prediction.

Ocular Therapeutix Stock Insights

Price Movement
In the last 3 months, OCUL stock has moved up by 74.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 10.63M → 13.45M (in $), with an average increase of 21.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -36.49M → -67.81M (in $), with an average decrease of 23.6% per quarter
OCUL vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 67.4% return, outperforming this stock by 11.8%
Price to Sales
ForOCUL every $1 of sales, investors are willing to pay $37.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.6 for every $1 of sales.

Ocular Therapeutix Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$4.2M	↑ 112.41%
Net Income	$-89.9M	↑ 55.89%
Net Profit Margin	-2.1K%	↑ 771.47%

	FY20	Y/Y Change
Revenue	$17.4M	↑ 311.71%
Net Income	$-159.6M	↑ 77.5%
Net Profit Margin	-917.26%	↑ 1210.37%

	FY21	Y/Y Change
Revenue	$43.5M	↑ 150.08%
Net Income	$-10.8M	↓ 93.23%
Net Profit Margin	-24.82%	↑ 892.44%

	FY22	Y/Y Change
Revenue	$51.5M	↑ 18.32%
Net Income	$-63.4M	↑ 487.02%
Net Profit Margin	-123.16%	↓ 98.34%

	FY23	Y/Y Change
Revenue	$58.4M	↑ 13.49%
Net Income	$-80.7M	↑ 27.3%
Net Profit Margin	-138.14%	↓ 14.98%

	FY24	Y/Y Change
Revenue	$63.7M	↑ 9.03%
Net Income	$-193.5M	↑ 139.68%
Net Profit Margin	-303.67%	↓ 165.53%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$14.7M	↓ 0.59%
Net Income	$-64.8M	↑ 121.93%
Net Profit Margin	-440.69%	↓ 243.28%

	Q2 FY24	Q/Q Change
Revenue	$16.4M	↑ 11.73%
Net Income	$-43.8M	↓ 32.49%
Net Profit Margin	-266.27%	↑ 174.42%

	Q3 FY24	Q/Q Change
Revenue	$15.4M	↓ 6.18%
Net Income	$-36.5M	↓ 16.64%
Net Profit Margin	-236.58%	↑ 29.69%

	Q4 FY24	Q/Q Change
Revenue	$17.1M	↑ 10.74%
Net Income	$-48.4M	↑ 32.6%
Net Profit Margin	-283.27%	↓ 46.69%

	Q1 FY25	Q/Q Change
Revenue	$10.6M	↓ 37.75%
Net Income	$-64.1M	↑ 32.37%
Net Profit Margin	-602.34%	↓ 319.07%

	Q2 FY25	Q/Q Change
Revenue	$13.5M	↑ 26.57%
Net Income	$-67.8M	↑ 5.87%
Net Profit Margin	-503.86%	↑ 98.48%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$1.9M	↑ 24.72%

	FY20	Y/Y Change
Profit	$15.3M	↑ 705.47%

	FY21	Y/Y Change
Profit	$39.1M	↑ 155.33%

	FY22	Y/Y Change
Profit	$47.0M	↑ 20.04%

	FY23	Y/Y Change
Profit	$53.2M	↑ 13.22%

	FY24	Y/Y Change
Profit	$58.1M	↑ 9.28%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$13.4M	↓ 0.2%

	Q2 FY24	Q/Q Change
Profit	$14.9M	↑ 11.52%

	Q3 FY24	Q/Q Change
Profit	$13.9M	↓ 7.15%

	Q4 FY24	Q/Q Change
Profit	$15.9M	↑ 14.34%

	Q1 FY25	Q/Q Change
Profit	$9.4M	↓ 40.88%

	Q2 FY25	Q/Q Change
Profit	$11.5M	↑ 22.87%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-77.6M	↑ 57.59%
Investing Cash Flow	$-2.2M	↑ 18.48%
Financing Cash Flow	$75.3M	↑ 9.76%

	FY20	Y/Y Change
Operating Cash Flow	$-53.6M	↓ 30.97%
Investing Cash Flow	$-841.0K	↓ 62.42%
Financing Cash Flow	$228.0M	↑ 202.64%

	FY21	Y/Y Change
Operating Cash Flow	$-65.6M	↑ 22.4%
Investing Cash Flow	$-1.2M	↑ 41.97%
Financing Cash Flow	$2.9M	↓ 98.75%

	FY22	Y/Y Change
Operating Cash Flow	$-59.6M	↓ 9.07%
Investing Cash Flow	$-3.7M	↑ 211.14%
Financing Cash Flow	$1.5M	↓ 49.0%

	FY23	Y/Y Change
Operating Cash Flow	$-70.2M	↑ 17.84%
Investing Cash Flow	$-6.1M	↑ 63.85%
Financing Cash Flow	$169.8M	↑ 11580.06%

	FY24	Y/Y Change
Operating Cash Flow	$-134.7M	↑ 91.75%
Investing Cash Flow	$-1.3M	↓ 78.84%
Financing Cash Flow	$332.1M	↑ 95.56%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-33.9M	↑ 96.22%
Investing Cash Flow	$-255.0K	↓ 44.44%
Financing Cash Flow	$321.2M	↑ 211.91%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-24.8M	↓ 26.81%
Investing Cash Flow	$-742.0K	↑ 190.98%
Financing Cash Flow	$2.2M	↓ 99.32%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-36.6M	↑ 47.4%
Investing Cash Flow	$-89.0K	↓ 88.01%
Financing Cash Flow	$4.2M	↑ 90.26%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-39.4M	↑ 7.85%
Investing Cash Flow	$-202.0K	↑ 126.97%
Financing Cash Flow	$4.5M	↑ 8.02%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-44.7M	↑ 13.29%
Investing Cash Flow	$-1.9M	↑ 856.93%
Financing Cash Flow	$4.2M	↓ 7.31%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-55.2M	↑ 23.66%
Investing Cash Flow	$-1.1M	↓ 42.32%
Financing Cash Flow	$97.8M	↑ 2238.18%

Ocular Therapeutix Technicals Summary

Sell

Neutral

Buy

Ocular Therapeutix is currently in a neutral trading position according to technical analysis indicators.

Ocular Therapeutix Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ocular Therapeutix Inc	9.6%	75.28%	44.56%	141.3%	49.53%
Regeneron Pharmaceuticals, Inc.	6.39%	-14.65%	-51.51%	-6.14%	-7.82%
Beone Medicines Ltd	10.08%	34.96%	66.94%	83.8%	36.85%
Vertex Pharmaceuticals Incorporated	-14.33%	-15.0%	-19.52%	31.35%	45.44%
Alnylam Pharmaceuticals, Inc.	40.06%	79.56%	63.55%	107.86%	227.15%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ocular Therapeutix Inc	NA	NA	0.0	-1.49	-0.63	-0.31	NA	1.77
Regeneron Pharmaceuticals, Inc.	14.62	14.62	1.19	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.94	27.94	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ocular Therapeutix Inc	Buy	$2.2B	49.53%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.5B	-7.82%	14.62	31.37%
Beone Medicines Ltd	NA	$38.8B	36.85%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.7B	45.44%	27.94	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.0B	227.15%	NA	-12.96%

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Organization	Ocular Therapeutix
Employees	274
CEO	Dr. Pravin U. Dugel M.D.
Industry	Health Technology

Key Management of Ocular Therapeutix Inc

Name	Title
Dr. Pravin U. Dugel M.D.	Executive Chairman, President & CEO
Dr. Jeffrey S. Heier M.D.	Chief Scientific Officer
Dr. Peter K. Kaiser M.D.	Chief Development Officer
Mr. Donald Notman Jr.	CFO, COO & Principal Accounting Officer
Dr. Peter K. Jarrett Ph.D.	Chief Technical Officer
Mr. William S. Slattery Jr.	Vice President of Investor Relations
Mr. Todd D.C. Anderman J.D.	Chief Legal Officer & Corporate Secretary
Mr. William H. Ransone II	Vice President of Global Sales & Marketing
Mr. Barry Rubenstein M.S.	Chief Human Resources Officer
Mr. Steve Meyers	Chief Commercial Officer

Important FAQs about investing in OCUL Stock from India :

What is Ocular Therapeutix share price today?

Ocular Therapeutix share price today is $12.37 as on August 18, 2025 at 11:48 PM IST. Ocular Therapeutix share today touched a day high of $12.65 and a low of $12.22.

What is the 52 week high and 52 week low for Ocular Therapeutix share?

Ocular Therapeutix share touched a 52 week high of $12.91 and a 52 week low of $5.79. Ocular Therapeutix stock price today, August 18, 2025 at 11:48 PM IST is trending at $12.37, lower by 4.18% versus the 52 week high.

How to invest in Ocular Therapeutix Stock (OCUL) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Ocular Therapeutix on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ocular Therapeutix Shares that will get you 0.1213 shares as per Ocular Therapeutix share price of $12.37 per share as on August 18, 2025 at 11:48 PM IST.

What is the minimum amount required to buy Ocular Therapeutix Stock (OCUL) from India?

Indian investors can start investing in Ocular Therapeutix (OCUL) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Ocular Therapeutix stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Ocular Therapeutix share’s latest price of $12.37 as on August 18, 2025 at 11:48 PM IST, you will get 0.8084 shares of Ocular Therapeutix. Learn more about fractional shares .

What are the returns that Ocular Therapeutix has given to Indian investors in the last 5 years?

Ocular Therapeutix stock has given 49.53% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?